Vancomycin dosing and monitoring 2 years after the guidelines

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 6, 2011, Pages 657-667

  Lomaestro, Ben M ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

generic; MIC creep; monitoring; MRSA; nephrotoxicity; obesity; renal failure; vancomycin

Indexed keywords

CREATININE; FUROSEMIDE; GENERIC DRUG; LINEZOLID; TELAVANCIN; VANCOMYCIN;

ACTUAL BODY WEIGHT; AGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL PERITONITIS; BACTERIAL VIRULENCE; BIOEQUIVALENCE; BODY WEIGHT; BURN PATIENT; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG MONITORING; DRUG PENETRATION; DRUG PROTEIN BINDING; HEALTHCARE ASSOCIATED PNEUMONIA; HEARING LOSS; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; KIDNEY FUNCTION; LEAN BODY WEIGHT; LOADING DRUG DOSE; LUNG; MAINTENANCE DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; MORTALITY; MUSCLE INJURY; NAUSEA; NECROTIZING FASCIITIS; NEPHROTOXICITY; NONHUMAN; OBESITY; OSTEOMYELITIS; OTOTOXICITY; PNEUMONIA; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HUMANS; KIDNEY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY; STAPHYLOCOCCAL INFECTIONS; TREATMENT FAILURE; VANCOMYCIN;

EID: 79959757176     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.46     Document Type: Article

References (70)

1. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66(1), 82-98 (2009
2. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52, e18-e55 (2011
3. Gould IM, Cauda R, Esposito S et al. Management of serious methicillin-resistant Staphylococcus aureus infections: what are the limits? Int. J. Antimicrob Agents 37, 202-209 (2011
4. Kanh AR, Kahn S, Zimmerman V, Baddour LM, Tieyjeh IM. Quality and strength of evidence of the Infectious Diseases Society of America Clinical Practice Guidelines. Clin. Infect. Dis. 51(10), 1147-1156 (2010
5. Deresinski S. Guiding clinical care through evidence-free zones. Editorial commentary. Clin. Infect. Dis. 51(10), 1157-1159 (2010
6. Guyatt G, Akl EA, Hirsh J et al. The vexing problem of guidelines and conflict of interest: a potential solution. Ann. Intern. Med. 152, 738-741 (2010
7. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44(11), 3883-3886 (2006 (Pubitemid 44737223)
8. Chua K, Howden BP. Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive-antibiotics. Curr. Opin. Infect. Dis. 22, 525-534 (2009
9. Leonard SN, Rossi KL, Newton KL, Rybak MJ. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother. 63, 489-492 (2009
10. Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53, 3162-3165 (2009
11. Prakash V, Lewis JS 2nd, Jorgensen JH. Vancomycin MICs with methicillin-resistant Staphylococcus aureus (MRSA) isolates differ based upon the susceptibility test method used. Antimicrob. Agents Chemother. 52(12), 4528 (2008
12. Hidayat LK, Hsu DI, Quist K, Shriner A, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166, 2138-2144 (2006 (Pubitemid 44631403)
13. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52(9), 3315-3320 (2008
14. Haque NZ, Zuniga LC, Peyrani P et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilatory-associated, or health-care associated pneumonia. Chest 238(6), 1356-1362 (2010
15. Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between clinical outcome of Staphylococcus aureus bacteremia and minimum inhibitory concentration of vancomycin. Clin. Infect. Dis. 48, 997-998 (2009
16. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC, Eliopoulos G. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J. Infect. Dis. 199, 532-536 (2009
17. Lalueza A, Chaves F, San Juan R, Daskalaki M, Otero JR, Aguado JM. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J. Infect. Dis. 201, 311-313 (2010
18. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46, 193-200 (2008 (Pubitemid 351269157)
19. Leonard SN, Rybak MJ. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/ pharmacodynamic model with simulated endocardial vegetations. J. Antimicrob. Chemother. 63, 155-160 (2009
20. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin failure. Clin. Infect. Dis. 38, 1700-1705 (2004 (Pubitemid 38781661)
21. Tsuji BT, Harigaya Y, Lesse AJ, Sakoulas G, Mylotte JM. Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density. Diag. Microbiol. Infect. Dis. 64, 220-224 (2009
22. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23(1), 99-139 (2010
23. Yang Y, McBride MV, Rodvold KA et al. Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus. Am. J. Health Syst. Pharm. 67, 1017-1024 (2010
24. Craig WA, Andes DR. In vivo pharmacodynamics of vancomycin against VISA, heteroresistant VISA (hVISA) and VSSA in the neutropenic murine thigh-infection model. Programs and Abstracts of the 46th Interscience Congress of Antimicrobial Agents and Chemotherapy (ICAACSan Francisco, CA, USA (2006) (Abstract A-644
25. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of b-lactams, glycopeptides and linezolid. Infect. Dis. Clin. N. Am. 17, 479-501 (2003 (Pubitemid 38029149)
26. Ebert S. In vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and -resistant S. aureus. Programs and Abstracts of the 27th Interscience Congress of Antimicrobial Agents and Chemotherapy (ICAACNew York, NY, USA (1987) (Abstract 439
27. Moise-Broder PA, Forrest A, Birmingham MC, Schentag J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43(13), 925-942 (2004 (Pubitemid 39447034)
28. Dehority W. Use of vancomycin in pediatrics. Ped. Infect. Dis. J. 29(5), 462-464 (2010
29. DeRyke CA, Alexander DP. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve/ minimum inhibitory concentration. Hosp. Pharm. 44(9), 751-765 (2009
30. Drusano GL, Rubino CM, Ambrose PG et al. Penetration of vancomycin (V) into epithelial lining fluid (ELFPrograms and Abstracts of the 47th Interscience Congress of Antimicrobial Agents and Chemotherapy (ICAACChicago, IL, USA (2007) (Abstract A-11
31. Harigaya Y, Bulitta JB, Forrest A et al. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin- resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob. Agents Chemother. 53(9), 3894-3901 (2009
32. American Thoracic society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Resp. Crit. Care Med. 171, 388-416 (2005
33. Stryjewski ME, Graham DR, Wilson SE et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin. Infect. Dis. 46, 1683-1693 (2008 (Pubitemid 351706765)
34. Kettle JK, Grace JW, Schaefer S, Desai A. Treatment of methicillin-resistant Staphylococcus aureus with a vancomycin minimum inhibitory concentration of 2 mcg/ml. Hosp. Pharm. 45(5), 375-380 (2010
35. Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 49, 1072-1079 (2009
36. Han PY, Dufful SB, Kirkpatrick CMJ, Green B. Dosing in obesity: a simple solution to a big problem. Clin. Pharmacol. Therapeut. 82(5), 505-508 (2007 (Pubitemid 47622534)
37. Barraclough K, Harris M, Montessori V, Levin A. An unusual case of acute kidney injury due to vancomycin - lessons learnt from reliance on eGFR. Nephrol. Dial. Transplant. 22, 2391-2394 (2007 (Pubitemid 47244726)
38. Young JF, Luecke RH, Pearce BA et al. Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data. J. Toxicol. Environ. Health. Part A 72, 527-540 (2009
39. Pai M. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv. Chron. Kid. Dis. 17(5), e53-e62 (2010
40. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int. 77, 760-764 (2010
41. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Ped. Infect. Dis. J. 28(5), 398-402 (2009
42. Elligsen M, Walker SAN, Walker SE, Simor A. Optimizing initial vancomycin dosing in burn patients. Burns 37(3), 406-414 (2010
43. Revilla N, Martin-Suarez A, Perez MP, Gonzalez FM, del Mar Fernandez de Gatta M. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/ pharmacodynamic simulation. Br. J. Clin. Pharmacol. 70(2), 201-212 (2010
44. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 45(9), 2460-2467 (2001 (Pubitemid 32801896)
45. Ingram PAR, Lye DC, Fisher DA, Goh WP, Tam VH. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int. J. Antimicrob. Agents 34(6), 570-574, (2009
46. Jeurissen A, Sluyts I, Rutsaert R. A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int. J. Antimicrob. Agents 37(1), 75-77 (2010
47. Ingram PR, Lye DC, Tambyah PA et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J. Antimicrob. Chemother. 62, 168-171 (2008 (Pubitemid 351865892)
48. Pea F, Furlanut M, Negri C et al. Prospectively validated dosing nomograms for maximizing pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob. Agents Chemother. 53(5), 1863-1867 (2009
49. Pea F, Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin. Pharmacokinet. 47(3), 147-152 (2008
50. Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Muller M, Tschernko E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery. Antesthesiol. 111(2), 356-365 (2009
51. Rybak MJ, Lomaestro B, Rotschafer J, Moellering RC, Levine DP. Reply to Panday and Sturkenboom. Clin. Infect. Dis. 49, 1965 (2009
52. Panday PN, Sturkenboom M. Continuous infusion of vancomycin less effective and safe than intermittent infusion, based on pharmacodynamic and pharmacokinetic principles. Clin. Infect. Dis. 49, 1964-1965 (2009
53. Ahmida MHS. Protective role of curcumin in nephrotoxic oxidative damage induced by vancomycin in rats. Exp. Toxicol. Pathol. DOI:10.1016/j.etp.2010.07. 010 (2010) (Epub ahead of print
54. Dieterich C, Puey A, Lyn S et al. Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol. Sci. 107(1), 258-269 (2009
55. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2), R31 (2007
56. Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C. The first international consensus conference on continuous renal replacement therapy. Kidney Int. 62, 1855-1863, (2002 (Pubitemid 35286296)
57. Goodsaid FM, Blank M, Dieterle R et al. Novel biomarkers of acute kidney toxicity. Nature 86(5), 490-496 (2009
58. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am. J. Med. 123(2), 182; e1-e7 (2010
59. Jeffres MN, Isakow W, Doherty JA et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin. Ther. 29(6), 1107-1115 (2007 (Pubitemid 47208584)
60. Lodise TP, Lomaestro B, Graves J, Drusano GL. Large vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52(4), 1330-1336 (2008 (Pubitemid 351521995)
61. Kunkel M, Chastre JE, Kolleff M et al. Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus. Programs and Abstracts of the IDSA 48th Annual Meeting. Vancouver Canada (2010) (Abstract LB49
62. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49, 507-514 (2009
63. Ladino M, Alex M, Mattiazzi A, Sadhu S, Schulman IH. Acute reversible vancomycin nephrotoxicity: case reports. J. Nephrol. Renal Transplant. 1(1), 4-10 (2008
64. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int. J. Antimicrob. Agents 37(2), 95-101 (2010
65. McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence of risk factors influencing the development of vancomycin nephrotoxicity in children. J. Pediatr. 158(3), 422-426 (2010
66. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increased doses. Antimicrob. Agents Chemother. 53(2), 483-486 (2009
67. Shields RK, Martello JL, Potoski BA. Is vancomycin ototoxicity a significant risk? Antimicrob. Agents Chemother. 53(10), 4572-4573 (2009
68. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents Chemother. 54(5), 3271-3279 (2010
69. Fujimura S, Watanabe A, Fuse K, Kikuchi T, Bomi K, Tokue Y. In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin. Int. J. Antimicrob. Agents 31, 380-399 (2008
70. Rodriguez CA, Agudelo M, Catano JC, Zuluaga AF, Vesga O. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J. Infect. 59, 277-280 (2009